AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27814709 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint herbal plaster treatments (4 applications using moxibustion technique)
Number of subjects: 23
Study 27814709 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint herbal plaster treatments
Number of subjects: 23
Study 27814712 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light therapy (BLT)
Number of subjects: 500
Study 27814717 — intervention group
Group type: EXPERIMENTAL
Intervention: Differentially methylated CpG probes associated with COPD
Number of subjects: 362
Study 27814717 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted gene coexpression network analysis (WGCNA)
Number of subjects: 362
Study 27814717 — intervention group
Group type: EXPERIMENTAL
Intervention: Differentially methylated CpG sites
Number of subjects: 362
Study 27814739 — intervention group
Group type: EXPERIMENTAL
Intervention: CTO-PCI
Number of subjects: 29
Study 27814763 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (IPTp-SP)
Number of subjects: 31493
Study 27814763 — intervention group
Group type: COMPARATOR
Intervention: Control (Counterfactual)
Number of subjects: 31493
Study 27814763 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal care utilization
Number of subjects: 31493
Study 27814763 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost of delivering three doses of SP
Number of subjects: 31493
Study 27815268 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy
Number of subjects: 2428
Study 27815290 — intervention group
Group type: EXPERIMENTAL
Intervention: Eversense implantable CGM sensor
Number of subjects: 71
Study 27815383 — intervention group
Group type: EXPERIMENTAL
Intervention: JE-CV booster
Number of subjects: 47
Study 27815401 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-chain recombinant tissue plasminogen activator (rtPA)
Number of subjects: 1004
Study 27815915 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every other week for 16 weeks
Number of subjects: 1212
Study 27815915 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 1212
Study 27815915 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1212
Study 27816492 — intervention group
Group type: EXPERIMENTAL
Intervention: Tremelimumab (3.5 and 10mg/kg i.v.) every 4 weeks for 6 doses, followed by 3-monthly infusions until off-treatment criteria were met.
Number of subjects: 32
Study 27816492 — intervention group
Group type: EXPERIMENTAL
Intervention: Tremelimumab in combination with subtotal radiofrequency ablation or chemoablation.
Number of subjects: 32
Study 27816492 — intervention group
Group type: EXPERIMENTAL
Intervention: Tremelimumab in combination with tumor ablation.
Number of subjects: 32
Study 27817208 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 3.0 mg
Number of subjects: 4725
Study 27817208 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4725
Study 27817951 — intervention group
Group type: EXPERIMENTAL
Intervention: INTUITY rapid deployment aortic valve replacement (RDAVR) system
Number of subjects: 839
Study 27817951 — intervention group
Group type: EXPERIMENTAL
Intervention: INTUITY RDAVR
Number of subjects: 839
Study 27820636 — intervention group
Group type: EXPERIMENTAL
Intervention: Causative mutations identified by sequencing
Number of subjects: 79
Study 27820636 — intervention group
Group type: EXPERIMENTAL
Intervention: Insertions and deletions
Number of subjects: 79
Study 27820636 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutations predicted to affect splicing
Number of subjects: 79
Study 27820636 — intervention group
Group type: EXPERIMENTAL
Intervention: Single point mutations
Number of subjects: 79
Study 27820636 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype-phenotype correlation analysis
Number of subjects: 79
Study 27820654 — intervention group
Group type: EXPERIMENTAL
Intervention: Overfeeding diet with 3% protein
Number of subjects: 64
Study 27820654 — intervention group
Group type: EXPERIMENTAL
Intervention: Overfeeding diet with 75% carbohydrate
Number of subjects: 64
Study 27820654 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting
Number of subjects: 64
Study 27820654 — intervention group
Group type: COMPARATOR
Intervention: Fasting vs Overfeeding
Number of subjects: 64
Study 27820654 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher urinary epinephrine concentrations during fasting
Number of subjects: 64
Study 27820947 — intervention group
Group type: EXPERIMENTAL
Intervention: Survivors diagnosed in 1990 to 1999
Number of subjects: 14566
Study 27820947 — intervention group
Group type: EXPERIMENTAL
Intervention: Survivors with leukemia
Number of subjects: 14566
Study 27820947 — intervention group
Group type: EXPERIMENTAL
Intervention: Survivors with osteosarcoma
Number of subjects: 14566
Study 27820947 — intervention group
Group type: EXPERIMENTAL
Intervention: Survivors with chronic health conditions, demographic characteristics, and health habits
Number of subjects: 14566
Study 27820947 — intervention group
Group type: COMPARATOR
Intervention: Survivors diagnosed in 1970 to 1979
Number of subjects: 14566
Study 27821091 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza-related outpatient visits in patients <65 years
Number of subjects: 35000000
Study 27821091 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza-related outpatient visits in children 5-17 years and adults 18-64 years
Number of subjects: 35000000
Study 27821091 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza-related outpatient visits in children <5 years
Number of subjects: 35000000
Study 27821091 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza-related OM visits
Number of subjects: 35000000
Study 27821091 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza-attributable outpatient visits in infants <2 years and toddlers aged 2-4 years
Number of subjects: 35000000
Study 27821091 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza-related respiratory visits in seniors 65 years and older
Number of subjects: 35000000
Study 27821091 — intervention group
Group type: COMPARATOR
Intervention: UTI visits as a negative control
Number of subjects: 35000000
Study 27821091 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall outpatient care for respiratory illness attributable to influenza
Number of subjects: 35000000
Study 27821384 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 20-minute hand massages (experimental)
Number of subjects: 79
Study 27821384 — intervention group
Group type: COMPARATOR
Intervention: 3 20-minute hand holdings (active control)
Number of subjects: 79
Study 27821384 — intervention group
Group type: COMPARATOR
Intervention: 3 20-minute rest periods (passive control)
Number of subjects: 79
Study 27821451 — intervention group
Group type: EXPERIMENTAL
Intervention: Auranofin, 6 mg orally daily for 7 days
Number of subjects: 0
Study 27821473 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary mechanical thrombectomy (MT)
Number of subjects: 131
Study 27821473 — intervention group
Group type: COMPARATOR
Intervention: IV thrombolysis (IVT) followed by mechanical thrombectomy (MT)
Number of subjects: 131
Study 27821473 — intervention group
Group type: COMPARATOR
Intervention: Comparison of MT vs IVT+MT
Number of subjects: 131
Study 27821717 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy restriction (~20% reduced intake of energy from food)
Number of subjects: 0
Study 27821717 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced energy expenditure due to physical exercise (combined endurance- and strength-training)
Number of subjects: 0
Study 27822376 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance-guided high-intensity focused ultrasound (HIFU) treatment
Number of subjects: 107
Study 27822376 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life and symptom outcome assessment using the uterine fibroid symptom and quality of life questionnaire
Number of subjects: 107
Study 27822376 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety assessment through reported adverse events
Number of subjects: 107
Study 27822454 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic surgery for thoracic oncology
Number of subjects: 0
Study 27822454 — intervention group
Group type: COMPARATOR
Intervention: Video-assisted thoracoscopic surgery (VATS)
Number of subjects: 0
Study 27822900 — intervention group
Group type: EXPERIMENTAL
Intervention: FMISO intratumour distribution
Number of subjects: 10
Study 27822929 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS hydromorphone
Number of subjects: 553
Study 27825292 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute spondylolysis treatment
Number of subjects: 121
Study 27825292 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression analysis
Number of subjects: 121
Study 27825340 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led telecoaching programme consisting of 5 monthly telephone sessions of +/- 30 min
Number of subjects: 287
Study 27825340 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led telecoaching programme
Number of subjects: 287
Study 27825340 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider views on telecoaching
Number of subjects: 287
Study 27825364 — intervention group
Group type: EXPERIMENTAL
Intervention: MR-proADM biomarker evaluation
Number of subjects: 67
Study 27825374 — intervention group
Group type: EXPERIMENTAL
Intervention: Talinolol
Number of subjects: 55
Study 27825382 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 vaccine
Number of subjects: 276
Study 27825382 — intervention group
Group type: EXPERIMENTAL
Intervention: MAL1C-like antibodies
Number of subjects: 276
Study 27825636 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib 60 mg orally per day
Number of subjects: 26
Study 27825636 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Number of subjects: 26
Study 27825780 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-onset bipolar disorder (EOB)
Number of subjects: 555
Study 27825780 — intervention group
Group type: COMPARATOR
Intervention: Late-onset bipolar disorder (LOB)
Number of subjects: 555
Study 27826345 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Surgery
Number of subjects: 76
Study 27826345 — intervention group
Group type: COMPARATOR
Intervention: Conventional Treatment
Number of subjects: 76
Study 27826691 — intervention group
Group type: EXPERIMENTAL
Intervention: DRD2 C957T polymorphism T-allele carriers
Number of subjects: 128
Study 27826691 — intervention group
Group type: COMPARATOR
Intervention: DRD2 C957T polymorphism
Number of subjects: 128
Study 27827322 — intervention group
Group type: EXPERIMENTAL
Intervention: Peri-muscular adipose tissue cross-sectional area in women with PCOS
Number of subjects: 68
Study 27827322 — intervention group
Group type: COMPARATOR
Intervention: Adiponectin and thigh subcutaneous adipose tissue in women without PCOS
Number of subjects: 68
Study 27827324 — intervention group
Group type: EXPERIMENTAL
Intervention: Clipping
Number of subjects: 413
Study 27827324 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiographic vasospasm
Number of subjects: 413
Study 27827324 — intervention group
Group type: EXPERIMENTAL
Intervention: Early cerebral infarcts
Number of subjects: 413
Study 27828822 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescence imaging (FI) using indocyanine green (ICG) at 0.25 mg/kg IV-injected intraoperatively
Number of subjects: 14
Study 27828943 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective PI3Kγ inhibitor (IPI-549)
Number of subjects: 0
Study 27828943 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 27829180 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid challenge
Number of subjects: 40
Study 27829397 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based behavioral intervention to reduce sugar-sweetened beverage consumption
Number of subjects: 0
Study 27829430 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibodies to pRBC surface antigens
Number of subjects: 0
Study 27829430 — intervention group
Group type: EXPERIMENTAL
Intervention: Total IgG to pRBCs
Number of subjects: 0
Study 27829430 — intervention group
Group type: EXPERIMENTAL
Intervention: Opsonizing antibody
Number of subjects: 0
Study 27829430 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibodies to merozoite antigens and non-placental-binding IEs
Number of subjects: 0
Study 27829430 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibodies to placental-binding infected erythrocytes
Number of subjects: 0
Study 27829511 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants infected with HIV
Number of subjects: 3554
Study 27829511 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants exposed to but uninfected with HIV
Number of subjects: 3554
Study 27829511 — intervention group
Group type: COMPARATOR
Intervention: Unexposed infants
Number of subjects: 3554
Study 27830157 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology Enabled Health Coaching Program
Number of subjects: 0
Study 27830207 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Binocular Treatment (I-BiT™) with patching
Number of subjects: 50
Study 27830207 — intervention group
Group type: COMPARATOR
Intervention: Control group with patching only
Number of subjects: 50
Study 27830935 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-recorded measures of behavior in youths with OCD
Number of subjects: 39
Study 27830935 — intervention group
Group type: EXPERIMENTAL
Intervention: Free arrangement task
Number of subjects: 39
Study 27830935 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand washing task
Number of subjects: 39
Study 27830935 — intervention group
Group type: EXPERIMENTAL
Intervention: Arrangement of objects on contrasting carpets
Number of subjects: 39
Study 27830935 — intervention group
Group type: EXPERIMENTAL
Intervention: Video recording methodology
Number of subjects: 39
Study 27830935 — intervention group
Group type: COMPARATOR
Intervention: CY-BOCS
Number of subjects: 39
Study 27830957 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab plus fludarabine and cyclophosphamide
Number of subjects: 0
Study 27830957 — intervention group
Group type: COMPARATOR
Intervention: Fludarabine and cyclophosphamide
Number of subjects: 0
Study 27831501 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal antibody (mAb) therapy
Number of subjects: 199
Study 27832753 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin augmentation
Number of subjects: 388
Study 27832753 — intervention group
Group type: EXPERIMENTAL
Intervention: Caesarean section
Number of subjects: 388
Study 27832753 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe hypertensive disorders
Number of subjects: 388
Study 27832753 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure recording during active labour
Number of subjects: 388
Study 27832753 — intervention group
Group type: COMPARATOR
Intervention: Overall facility-based stillbirth rate
Number of subjects: 388
Study 27832753 — intervention group
Group type: EXPERIMENTAL
Intervention: Foetal heart rate assessment
Number of subjects: 388
Study 27832799 — intervention group
Group type: EXPERIMENTAL
Intervention: VMAT (Volumetric Modulated Arc Therapy)
Number of subjects: 25
Study 27832799 — intervention group
Group type: COMPARATOR
Intervention: 3DCRT (3D Conformal Radiotherapy)
Number of subjects: 25
Study 27832799 — intervention group
Group type: EXPERIMENTAL
Intervention: VMAT (5x5 Gy)
Number of subjects: 25
Study 27832799 — intervention group
Group type: COMPARATOR
Intervention: 3DCRT (5x5 Gy)
Number of subjects: 25
Study 27832799 — intervention group
Group type: EXPERIMENTAL
Intervention: VMAT
Number of subjects: 25
Study 27832799 — intervention group
Group type: COMPARATOR
Intervention: 3DCRT
Number of subjects: 25
Study 27832799 — intervention group
Group type: EXPERIMENTAL
Intervention: VMAT (25x1.8 Gy)
Number of subjects: 25
Study 27832799 — intervention group
Group type: EXPERIMENTAL
Intervention: VMAT and 3DCRT
Number of subjects: 25
Study 27832799 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated schedule
Number of subjects: 25
Study 27832799 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal life expectancy
Number of subjects: 25
Study 27832850 — intervention group
Group type: EXPERIMENTAL
Intervention: CTO crossing device
Number of subjects: 1006
Study 27832850 — intervention group
Group type: COMPARATOR
Intervention: Wire-catheter approach
Number of subjects: 1006
Study 27833752 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical Care Pain Observation Tool (CPOT)
Number of subjects: 101
Study 27833752 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Pain Scale (BPS)
Number of subjects: 101
Study 27833752 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of CPOT and BPS
Number of subjects: 101
Study 27833752 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Analog Scale (VAS)
Number of subjects: 101
Study 27834029 — intervention group
Group type: EXPERIMENTAL
Intervention: Opiorphin levels in iBMS patients
Number of subjects: 21
Study 27834029 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 21
Study 27834029 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood opiorphin levels
Number of subjects: 21
Study 27834029 — intervention group
Group type: COMPARATOR
Intervention: Salivary opiorphin levels
Number of subjects: 21
Study 27834029 — intervention group
Group type: COMPARATOR
Intervention: Urinary opiorphin levels
Number of subjects: 21
Study 27834663 — intervention group
Group type: EXPERIMENTAL
Intervention: iFR (instantaneous wave-free ratio)
Number of subjects: 197
Study 27834663 — intervention group
Group type: EXPERIMENTAL
Intervention: Pd/Pa (distal coronary to aortic pressure ratio)
Number of subjects: 197
Study 27834663 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid strategy incorporating iFR or Pd/Pa
Number of subjects: 197
Study 27834663 — intervention group
Group type: COMPARATOR
Intervention: FFR (fractional flow reserve)
Number of subjects: 197
Study 27834750 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients deemed too good for intravenous tissue-type plasminogen activator
Number of subjects: 380
Study 27834750 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, initial National Institutes of Health Stroke Scale, and infarct location
Number of subjects: 380
Study 27834778 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippocampus and BF volumetry in primary care
Number of subjects: 71
Study 27834778 — intervention group
Group type: EXPERIMENTAL
Intervention: White matter lesions
Number of subjects: 71
Study 27834778 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippocampus and BF volumetry
Number of subjects: 71
Study 27835722 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive brexpiprazole (target dose: 3 mg/d)
Number of subjects: 44
Study 27835869 — intervention group
Group type: EXPERIMENTAL
Intervention: OTX015 (MK-8628)
Number of subjects: 0
Study 27836022 — intervention group
Group type: EXPERIMENTAL
Intervention: LVAD therapy
Number of subjects: 0
Study 27836022 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical management
Number of subjects: 0
Study 27836288 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 955
Study 27836288 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed feeding
Number of subjects: 955
Study 27836288 — intervention group
Group type: COMPARATOR
Intervention: Formula feeding
Number of subjects: 955
Study 27836676 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline IL-6 (quarters)
Number of subjects: 192
Study 27836676 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline IL-17F (highest quarters vs others)
Number of subjects: 192
Study 27836676 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline IL-23 (highest quarters vs others)
Number of subjects: 192
Study 27836676 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline IL-17A
Number of subjects: 192
Study 27836716 — intervention group
Group type: EXPERIMENTAL
Intervention: Brigatinib 180 mg once daily
Number of subjects: 137
Study 27836716 — intervention group
Group type: EXPERIMENTAL
Intervention: Brigatinib 90 mg once daily
Number of subjects: 137
Study 27836716 — intervention group
Group type: EXPERIMENTAL
Intervention: Brigatinib 180 mg once daily with a 7 day lead-in at 90 mg
Number of subjects: 137
Study 27836716 — intervention group
Group type: EXPERIMENTAL
Intervention: Brigatinib
Number of subjects: 137
Study 27836815 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based guided self-help CBT intervention
Number of subjects: 0
Study 27836815 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 0
Study 27836860 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus as primary therapy
Number of subjects: 0
Study 27837749 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained inflation
Number of subjects: 0
Study 27837749 — intervention group
Group type: COMPARATOR
Intervention: Intermittent positive pressure ventilation with positive end-expiratory pressure
Number of subjects: 0
Study 27838305 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic valve replacement (AVR)
Number of subjects: 0
Study 27839651 — intervention group
Group type: EXPERIMENTAL
Intervention: SARA
Number of subjects: 605
Study 27839651 — intervention group
Group type: EXPERIMENTAL
Intervention: INAS
Number of subjects: 605
Study 27839651 — intervention group
Group type: EXPERIMENTAL
Intervention: SCAFI
Number of subjects: 605
Study 27839651 — intervention group
Group type: EXPERIMENTAL
Intervention: ADL
Number of subjects: 605
Study 27839651 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D-3L
Number of subjects: 605
Study 27839651 — intervention group
Group type: EXPERIMENTAL
Intervention: PVF
Number of subjects: 605
Study 27839782 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5mg/kg ketamine infusion
Number of subjects: 93
Study 27839979 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy (ERT) with velaglucerase alfa
Number of subjects: 39
Study 27840583 — intervention group
Group type: EXPERIMENTAL
Intervention: RRx-001 followed by reintroduced platinum doublets
Number of subjects: 1
Study 27840583 — intervention group
Group type: COMPARATOR
Intervention: Platinum doublets
Number of subjects: 1
Study 27841040 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal calprotectin
Number of subjects: 68
Study 27841040 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal lactoferrin
Number of subjects: 68
Study 27841040 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic (ROC) curve for fecal calprotectin
Number of subjects: 68